Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tips Industries Ltd
NSE:TIPSINDLTD
|
IN |
|
Nephros Inc
NASDAQ:NEPH
|
US |
|
Jaypee Infratech Ltd
NSE:JPINFRATEC
|
IN |
|
Bank Sankt-Peterburg PAO
MOEX:BSPB
|
RU |
|
B
|
Black Pearl SA
WSE:BPC
|
PL |
|
A
|
AnGes Inc
OTC:AMGXF
|
JP |
|
S
|
Shenzhen SC New Energy Technology Corp
SZSE:300724
|
CN |
|
I
|
ImmunoGen Inc
XETRA:IMU
|
US |
|
Meiji Holdings Co Ltd
OTC:MEJHY
|
JP |
|
T
|
TeamViewer AG
XETRA:TMV
|
DE |
Novan Inc
Accrued Liabilities
Novan Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Accrued Liabilities
$18.8m
|
CAGR 3-Years
71%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$32.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
9%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$13.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$14.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$19.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Accrued Liabilities?
Accrued Liabilities
18.8m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Accrued Liabilities amounts to 18.8m USD.
What is Novan Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
27%
Over the last year, the Accrued Liabilities growth was 277%. The average annual Accrued Liabilities growth rates for Novan Inc have been 71% over the past three years , 27% over the past five years .
